Damora Therapeutics
DMRA
20.24
+0.69
+3.53%
Damora Therapeutics
US · DMRA
#3109 by market cap
Listed 1970
20.24
+0.69
+3.53%
Live - 5344 symbols - heartbeat 474s ago
· 2026-10-07 19:54
After-hours
20.24
0.00%
- Market cap
- 1.25B
- P/E (TTM)i
- -77.85
- P/Bi
- 3.24
- EPSi
- -3.98
- Div yieldi
- 0.00%
- 52W posi
- 46%
Reader sentiment
Are you bullish or bearish on DMRA?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 2.81M | 2.45M | 9.01M | 13.74M | 13.00M | 12.69M | 10.50M | 9.69M |
| Research & development | 10.09M | 36.53M | 24.63M | 38.49M | 48.21M | 23.77M | 10.79M | 201.19M |
| Operating profit | -12.91M | -38.97M | -33.64M | -52.23M | -61.21M | -36.46M | -21.29M | -210.87M |
| Pretax profit | -15.87M | -36.51M | -34.84M | -51.75M | -61.62M | -38.35M | -21.40M | -209.79M |
| Tax | -- | -- | -- | -- | -- | 0 | 41.00K | 50.00K |
| Net profit | -15.87M | -36.51M | -34.84M | -51.75M | -61.62M | -38.35M | -21.44M | -209.84M |
| Basic EPS | -66 | -82 | -191 | -51 | -61 | -36 | -19 | -4 |
| Diluted EPS | -66.14 | -82.41 | -190.50 | -51.25 | -60.75 | -36.08 | -18.53 | -3.98 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.92M | 1.96M | 1.74M | 4.07M | 7.03M | 9.45M |
| Research & development | 678.00K | 1.47M | 1.42M | 197.63M | 23.78M | 25.54M |
| Operating profit | -2.60M | -3.42M | -3.16M | -201.70M | -30.81M | -34.99M |
| Pretax profit | -2.53M | -3.43M | -3.13M | -200.69M | -27.74M | -30.92M |
| Tax | 2.00K | 4.00K | 0 | 44.00K | 42.00K | 255.00K |
| Net profit | -2.53M | -3.44M | -3.13M | -200.74M | -27.78M | -31.17M |
| Basic EPS | -2 | -3 | -2 | 3 | -1 | 0 |
| Diluted EPS | -1.92 | -2.60 | -2.36 | 2.90 | -0.62 | -0.39 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 34.96M | 56.08M | 169.30M | 110.10M | 63.91M | 36.77M | 16.84M | 260.42M |
| Cash & ST investments | 30.99M | 11.29M | 163.58M | 100.19M | 60.22M | 33.15M | 14.18M | 257.62M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 35.10M | 56.61M | 171.60M | 122.22M | 73.19M | 38.23M | 17.13M | 260.53M |
| Total current liabilities | 4.44M | 7.93M | 5.57M | 4.54M | 11.11M | 5.83M | 1.20M | 20.07M |
| Short-term debt | -- | 87.00K | 374.00K | 399.00K | 476.00K | 183.00K | 12.00K | 15.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 17,858,000.00 | 21,552,000.00 | 6,107,000.00 | 4,992,000.00 | 11,435,000.00 | 5,896,000.00 | 1,301,000.00 | 20,147,000.00 |
| Total equity | 17.25M | 35.06M | 165.49M | 117.22M | 61.75M | 32.33M | 15.83M | 240.38M |
| Retained earnings | -33.02M | -69.52M | -104.36M | -156.11M | -217.74M | -256.09M | -277.52M | -487.36M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 14.92M | 13.03M | 9.79M | 260.42M | 535.41M | 543.59M |
| Cash & ST investments | 11.94M | 10.21M | 7.61M | 257.62M | 532.90M | 540.52M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 15.37M | 13.69M | 10.74M | 260.53M | 535.44M | 543.64M |
| Total current liabilities | 1.55M | 2.63M | 2.62M | 20.07M | 23.81M | 27.55M |
| Short-term debt | 13.00K | 15.00K | 15.00K | 15.00K | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 1,656,000.00 | 2,738,000.00 | 2,729,000.00 | 20,147,000.00 | 23,839,000.00 | 27,577,000.00 |
| Total equity | 13.71M | 10.95M | 8.01M | 240.38M | 511.60M | 516.06M |
| Retained earnings | -280.06M | -283.49M | -286.63M | -487.36M | -515.15M | -546.32M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -13.69M | -19.33M | -38.20M | -52.31M | -42.93M | -36.91M | -18.62M | -6.73M |
| Depreciation & amortization | 0 | 111.00K | 188.00K | 441.00K | 490.00K | 830.00K | 181.00K | 34.00K |
| Free cash flow | -13.69M | -19.33M | -38.20M | -52.53M | -43.13M | -36.91M | -18.62M | -6.73M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 88.47M | 0 | 507.00K | 2.88M | -- | -- |
| Ending cash balance | 31.13M | 11.53M | 163.84M | 62.56M | 32.79M | 21.47M | 14.18M | 257.62M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -2.44M | -2.24M | -2.62M | 566.00K | -20.60M | -21.87M |
| Depreciation & amortization | 8.00K | 9.00K | 10.00K | 7.00K | 68.00K | 11.00K |
| Free cash flow | -2.44M | -2.24M | -2.62M | 566.00K | -20.60M | -21.87M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | 295.50M | 50.72M |
| Ending cash balance | 11.94M | 10.21M | 7.61M | 257.62M | 532.90M | 540.52M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -73.85 | -36.61 | -68.86 | -81.52 | -91.62 | -- |
| ROA %i | -54.14 | -79.61 | -30.53 | -35.23 | -63.07 | -68.84 | -77.45 | -151.15 |
| ROIC %i | -- | -- | -72.92 | -36.49 | -69.03 | -84.17 | -94.57 | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -70.49 | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 7.87 | 7.07 | 30.42 | 24.23 | 5.75 | 6.31 | 14.07 | 12.98 |
| Quick ratioi | 7.20 | 6.61 | 29.79 | 22.55 | 5.55 | 5.98 | 12.58 | 12.88 |
| Debt / assetsi | 0.00 | 0.53 | 0.53 | 0.69 | 1.10 | 0.65 | 0.43 | 0.03 |
| LT debt / equityi | -- | -- | 0.33 | 0.38 | 0.53 | 0.20 | 0.42 | -- |
| Interest coveragei | -4.34 | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -91.32 | -99.96 | -114.81 | -- | -120.10 | -132.85 |
| ROA %i | -77.32 | -80.97 | -92.89 | -151.15 | -85.36 | -94.32 |
| ROIC %i | -93.37 | -101.87 | -117.22 | -- | -121.37 | -135.33 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 9.62 | 4.96 | 3.73 | 12.98 | 22.48 | 19.73 |
| Quick ratioi | 8.29 | 4.26 | 3.28 | 12.88 | 22.42 | 19.65 |
| Debt / assetsi | 0.48 | 0.55 | 0.67 | 0.03 | -- | -- |
| LT debt / equityi | 0.49 | 0.62 | 0.86 | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.